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Background.  The  mosquito-­‐‑borne  dengue  viruses  (DENV  1,  2,  3,  and  4)  have  a  rapidly  
expanding  geographic  range  and  have  become  endemic  in  over  100  countries  with  
tropical  and  subtropical  climates,  including  Sri  Lanka.  In  Sri  Lanka,  dengue  outbreaks  
have  occurred  primarily  in  Colombo,  the  capital,  since  the  1960s;  however,  recent  
reports  suggest  transmission  throughout  the  island,  with  a  second  focus  in  the  port  city  
of  Galle  in  the  Southern  Province.    
Methods.  To  better  assess  the  emergence  of  dengue  among  fever-­‐‑causing  agents  in  and  
around  Galle,  we  collected  epidemiological  and  clinical  characteristics,  as  well  as  acute  
and  convalescent  sera,  from  febrile  patients  of  1  year  of  age  or  older  without  a  defined  
source  between  June  1,  2012  and  June  30,  2013  at  the  Teaching  Hospital  of  Karapitiya.  
The  distribution  of  serotypes  was  compared  with  similar  data  collected  in  2007.    We  then  
performed  whole  genome  sequencing  on  40  dengue  isolates  from  Colombo  (n=20)  and  
Galle  (n=20)  from  2012-­‐‑13  to  assess  relatedness.      
Results.  Through  serological  testing  for  DENV  IgM  and  IgG  antibodies,  virus  isolation,  
and  molecular  testing,  we  confirmed  acute  dengue  in  64.8%  of  the  febrile  population.  
Dengue  serotype  distribution  in  2012  (DENV1  93.8%,  DENV4  6.2%)  differed  from  2007,  
(DENV2  10.5%,  DENV3  79%,  and  DENV4  10.5%).  Phylogenetic  analysis  of  whole  
genome  sequence  from  representative  samples  from  2012-­‐‑2013  demonstrated  that  most  
    
v  
DENV  1  strains  (25  of  26  tested)  from  both  Galle  and  Colombo  belonged  to  genotype  1  
and  were  closely  related  to  strains  previously  reported  in  Colombo  during  the  2009-­‐‑2010  
dengue  season.  All  DENV4  strains  (n=10  from  Galle  and  10  from  Colombo)  belonged  to  
genotype  1  and  were  most  closely  related  to  a  strain  from  Thailand.  These  results  
support  the  movement  of  dengue  virus  strains  from  Colombo  and  Galle,  but  the  timing  
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1. Background  
  
1.1  Global  Dengue  Burden  
Dengue  is  the  most  rapidly  spreading  mosquito-­‐‑borne  viral  disease.  Due  to  the  optimal  
environmental  conditions  of  the  tropical  and  subtropical  regions  of  the  world,  roughly  
3.6  billion  people  in  these  regions  are  at  risk  of  contracting  the  disease,  with  an  
estimated  390  million  new  infections  including  96  million  symptomatic  infections  and  2  
million  dengue  hemorrhagic  fever  (DHF)  cases  annually  on  a  global  scale  (WHO,  2012;  
Bhatt  et  al.,  2013;  Beatty  et  al.,  2008;  Figure  1).  Incidence  of  dengue  has  increased  30  fold  
in  the  past  50  years,  posing  a  public  health  threat  through  human  suffering,  health  
system  strain,  and  economic  losses  (WHO,  2012;  Figure  2).  Between  2000-­‐‑2009,  there  
were  nearly  5  million  cases  of  dengue  and  DHF  cases  worldwide.  
  




Figure  2:  Total  number  of  DF/DHF  cases  worldwide  reported  to  the  WHO  from  
1995  to  2009  (WHO  DengueNet,  2014)  
Although  often  asymptomatic,  dengue  fever  (DF)  is  the  most  common  
symptomatic  presentation  of  dengue  virus  (DENV)  infection.  Symptoms  range  from  
mild  to  incapacitating  febrile  illness  accompanied  by  headache,  bradycardia,  abdominal  
tenderness,  and  muscle,  joint  and  bone  pain  (Table  1;  WHO,  2013).  DHF  and  dengue  
shock  syndrome  (DSS)  are  more  severe  forms  of  DF  where  DHF  is  characterized  by  
excessive  plasma  leakage  selectively  into  pleural  and  peritoneal  cavities  accompanied  
with  persistent  vomiting,  bleeding  and  breathing  difficulty  (WHO,  2013).  DSS  cases  
have  all  of  the  DHF  symptoms  present  in  addition  to  shock,  or  circulatory  failure  (Table  
1).  WHO  has  changed  the  working  classification  of  dengue  infection  to  be  more  sensitive  
to  severe  dengue  (Figure  3;  Hadinegoro,  2012).  According  to  the  new  definitions,  
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approximately  2  million  people  are  estimated  to  develop  severe  dengue  infection  
annually  (Bhatt  et  al.,  2013).  The  case-­‐‑fatality  rate  is  estimated  to  be  2.5%  across  all  forms  
of  DENV  infections,  but  ranges  from  0.2%  to  5%  depending  on  severity  of  disease  and  
access  to  appropriate,  timely  health  care  (WHO,  2009).      
Table  1:  WHO  Definitions  of  Dengue  Fever,  Dengue  Hemorrhagic  Fever  and  
Dengue  Shock  Syndrome  (WHO,  1997)  
Dengue  Fever  
(DF)  
• Acute	  febrile	  illness	  with	  two	  of	  the	  following:	  
o Headache,	  retro-­‐orbital	  pain,	  myalgia,	  arthralgia,	  rash,	  hemorrhagic	  manifestations,	  leukopenia	  
• Supportive	  laboratory	  confirmation	  




All  of  the  following:  
• Acute	  febrile	  illness	  
• Hemorrhagic	  tendencies	  
• Thrombocytopenia	  
• Evidence	  of	  plasma	  leakage	  
Dengue  Shock  
Syndrome  (DSS)  
All  four  criteria  of  DHF  in  addition  to  circulatory  failure  
  
  
Figure  3:  WHO  Working  Dengue  Case  Classification  (WHO,  2009)  
  4  
With  dengue  affecting  a  large  portion  of  tropical  developing  nations,  
encompassing  a  half  of  the  world’s  population,  understanding  the  economic  impacts  of  
the  disease  is  critical.  Yet,  very  few  studies  have  been  conducted  to  assess  these  issues  in  
developing  nations.  In  2004,  an  estimated  annual  cost  of  US$236  million  was  lost  due  to  
DF,  DHF  and  DSS  treatment,  hospitalization,  transportation  and  productive  work  loss  in  
Southeast  Asia  (Shepard  et  al.,  2004).  Additionally  with  the  impact  of  dengue  outbreaks  
on  tourism,  the  Southeast  Asia  region  will  lose  an  estimated  US$2.36  billion  during  the  
next  decade,  or  a  comparable  264  disability-­‐‑adjusted  life  years  (DALYs)  per  million  
(population)  per  year  for  people  in  dengue  risk  areas  (Cattand  et  al.,  2006;  Suaya  et  al.,  
2006).  Although  the  economic  burden  of  DF  and  DHF  are  not  as  great  as  other  infectious  
diseases  like  malaria  and  HIV/AIDS,  the  existence  of  such  a  burden,  especially  
considering  the  cyclical  epidemic  pattern  of  dengue  outbreaks,  warrants  greater  
attention  to  decrease  and  prevent  disruption  in  people’s  lives.  
The  social  impacts  of  epidemics  are  difficult  to  quantify,  however,  are  great  
enough  to  cause  stress  in  health  care  systems  and  general  public’s  perception  of  public  
health  systems  and  the  government.  The  overall  ignorance  to  the  importance  of  
infectious  disease  surveillance  and  vector  control  in  the  latter  half  of  the  20th  century  
played  a  large  role  in  the  rise  of  emergence  and  re-­‐‑emergence  of  numerous  infectious  
diseases  globally,  especially  in  resource  limited  countries  that  do  not  have  the  financial  
or  infrastructural  capability  to  respond  quickly  to  epidemics  (Weiss  and  McMichael,  
  5  
2004).  In  the  case  of  dengue,  the  idea  of  living  from  epidemic  to  epidemic  has  been  
highlighted  through  the  lack  of  individual  involvement  in  vector  control  and  ineffective  
governmental  vector  control  programs  (Gubler,  2002;  Kendall  et  al.,  1991).  Varying  
levels  of  dengue  awareness  and  prevention  methods  surveyed  across  many  nations  
showed  that  commonalities  lie  in  misconception  of  the  disease  and  lack  of  knowledge  
and  participation  in  household-­‐‑level  vector  control  (Itrat  et  al.,  2008;  Winch  et  al.,  2002;  
Perez-­‐‑Guerra  et  al.,  2005).    Although  the  actual  social  impacts  are  difficult  to  measure,  
such  studies  suggest  the  importance  of  public  health  efforts  to  educate  the  public  on  the  
disease  and  to  emphasize  individual  involvement  in  vector  control.    
The  origins  of  DENV  are  not  clearly  understood  primarily  due  to  the  wide  
geospatial  spread  of  the  most  recent  common  ancestors  of  the  virus  (Weaver  and  
Vasilakis,  2009;  Kuno  et  al.,  1998).  Phylogenetic  and  E-­‐‑gene  sequencing  suggest  that  all  
endemic  DENV  serotypes  arose  from  their  sylvatic  counterparts  as  early  as  4000  years  
ago  (Weaver  and  Vasilakis,  2009;  Rico-­‐‑Hesse,  1990;  Wang  et  al.,  2000;  Gubler,  1997).  The  
first  epidemics  of  dengue  were  reported  in  Asia,  Africa  and  North  America  by  the  late  
18th  century,  but  the  overwhelming  burden  of  dengue  was  not  experienced  until  the  
post  WWII  era  (Gubler,  2006).    
In  the  mid  1950’s,  a  program  was  initiated  to  control  yellow  fever  through  the  
eradication  of  the  Ae.  aegypti  mosquito,  the  primary  vector  for  both  yellow  fever  virus  
(YFV)  and  DENV  populations  in  the  Americas  using  dichlorodiphenyltrichloroethane  
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(DDT).  This  effort  largely  reduced  mosquito  populations  in  the  Americas  and  
contributed  to  the  low  levels  of  dengue  cases  shortly  after  the  program  was  initiated  
(Gubler,  2004).  However,  in  the  40  years  since  the  DDT  program  was  halted  due  to  
environmental  concerns,  populations  of  Ae.  aegypti  mosquitoes  and  DENV  have  
exploded  (Figure  4)  and  the  disease  is  now  endemic  in  more  than  100  countries  across  
Africa,  the  Americas,  the  Western  Pacific,  the  Eastern  Mediterranean  and  south  and  
Southeast  Asia  (WHO,  2013).    
  
Figure  4:  Geographic  Distribution  of  DHF  in  the  Americas  pre-­‐‑1981  and  post-­‐‑
1981  (Gubler,  2011)  
  
   It  is  unlikely  that  the  rapid  spread  of  dengue  and  its  vector  is  due  to  a  single  
cause;  poorly  planned  urbanization,  global  connectivity  through  trade  and  air  travel  are  
all  thought  to  be  important  contributors.  A  large  percentage  of  urbanization  occurs  in  
less  developed  nations  where  the  annual  urban  population  rate  of  change  is  2.02%,  
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which  is  substantially  larger  than  the  0.52%  observed  in  more  developed  nations  (UN,  
2011).  The  Aedes  mosquito  is  predominantly  an  urban  mosquito  with  a  preference  for  
domestic  and  peridomestic  breeding.  Urban  cities  in  tropical  climates  with  rapidly  
increasing  populations  have  proven  to  be  particularly  prime  locations  for  feeding  and  
breeding  and  are  likely  to  increase  the  transmissibility  of  DENV  (Gubler,  2011).  
Furthermore,  urban  areas  in  less  developed  countries  also  serve  as  temporary  or  
permanent  residences  for  many  migratory  workers  who  do  travel  back  and  forth  to  their  
rural  homes,  providing  an  avenue  for  disease  transmission  to  occur  from  urban  to  rural  
areas.  Traveling  has  also  increased  on  an  international  scale.  Roughly  900  million  people  
traveled  internationally  in  the  past  year  (UN,  2013).  Increased  travel,  as  well  as  trade,  
potentially  allows  for  wider  spread  of  disease  and  vectors  across  countries  and  
continents  (Wilder-­‐‑Smith  and  Gubler,  2008).    
By  the  year  2020,  the  WHO  hopes  to  reduce  mortality  and  morbidity  from  
dengue  by  at  least  50%  and  25%  respectively,  compared  to  the  statistics  from  the  year  
2010  (WHO,  2012).  To  reach  their  goals,  the  WHO  has  proposed  a  multi-­‐‑faceted  
approach  that  highlights  the  importance  of  global  commitment  and  involvement  in  
improving  detection,  management,  and  control  of  both  disease  and  the  vector.  Of  the  3.6  
billion  people  currently  living  in  regions  of  DENV  risk,  nearly  75%  of  the  global  
population  exposed  to  dengue  is  in  the  Asia-­‐‑Pacific  region  (WHO,  2012).  Increased  
tourism  to  the  tropical  areas  with  Southeast  Asia  alone  reporting  248  million  incoming  
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tourists  for  2013  (WHO,  2012;  Kester,  2014)  highlights  the  difficulty  in  exposure  
management  in  a  fast-­‐‑moving  global  community.  Various  forms  of  prevention  and  
control  efforts  ranging  from  removal  of  breeding  sites  to  genetic  modifications  of  the  
vector  have  shown  varying  levels  of  success  (Wise  de  Valdez  et  al.,  2010;  Harris  et  al.,  
2011;  Eisen  and  Beaty,  2008).  Vector  control  is  highly  taxing  on  an  economical  and  
personal  commitment  level  and  its  lack  of  success  is  reflected  by  the  global  burden  of  
dengue  (Alphey  et  al.,  2010).    
To  date,  there  is  neither  specific  therapeutic  treatment  nor  preventative  vaccine  
available  for  dengue.  There  are  four  serotypes  of  DENV:  DENV-­‐‑1,  DENV-­‐‑2,  DENV-­‐‑3,  
and  DENV-­‐‑4  where  infection  from  one  serotype  provides  lifelong  serotype-­‐‑specific  
immunity  (Gubler,  1998)  and  only  2  months  on  average  of  cross  protection  from  the  
other  three  serotypes  (Snow  et  al.,  in  press).  Secondary  infections  of  DENV  are  believed  
to  be  more  severe  due  to  an  array  of  factors  such  as  patient  status  and  virus  strain  as  
well  as  the  antibody-­‐‑dependent  enhancement  (ADE)  theory  that  illustrates  the  
neutralizing  limitations  of  heterotypic  IgG  antibodies  (Thomas,  2008;  Halstead,  1998).    
Conventional  treatment  plans  for  dengue  currently  consist  of  analgesics  and  
fluid  replacement  therapy  since  there  is  no  pathogen  specific  treatment  (CDC,  2014).  
Hence,  developing  an  antiviral  drug  and/or  vaccine  that  effectively  covers  all  four  
serotypes  is  critical.  Currently,  there  are  six  tetravalent  vaccines  that  include  live-­‐‑
attenuated  candidate  vaccines  as  well  as  inactivated,  subunit  and  DNA  candidate  
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vaccines  (Gubler,  2011).  The  current  leader  in  creating  a  dengue  vaccine  is  Sanofi-­‐‑
Pasteur  who  has  recently  published  results  from  the  Phase  IIb  clinical  studies  in  
Thailand,  where  their  live-­‐‑attenuated,  chimeric  vaccine  was  found  to  be  effective  against  
three  out  of  the  four  circulating  serotypes  in  endemic  populations.  Phase  III  trials  are  
currently  underway  in  multiple  countries  where  positive  results  may  allow  for  vaccine  
rollout  to  begin  as  early  as  2017  (Whitehead  et  al.,  2007;  Durbin  et  al.,  2011;  Sabchareon  
et  al.,  2012;  Bernal,  2013).    
  
1.2  Virus  and  Vector  
DENV  genome  is  made  of  positive  sense  single  RNA  strand  that  encodes  a  single  
polypeptide  that  is  then  post-­‐‑translationally  processed  into  ten  mature  viral  proteins.  Of  
the  ten  proteins,  three  –  capsid,  envelope,  and  pre-­‐‑membrane  –  are  structural  proteins  
and  the  other  seven  –  NS1,  NS2A,  NS2B,  NS3,  NS4A,  NS4B,  and  NS5  –  are  non-­‐‑
structural  proteins  (Guzman  et  al.,  2010).    
DENV  are  mosquito-­‐‑borne  flaviviruses  that  are  primarily  transmitted  to  humans  
by  Aedes  stegomyia  species  mosquitoes.  Although  DENV  can  be  carried  by  various  
species  within  the  Aedes  genus  including  Ae.  albopictus,  Ae.  polynesiensis  and  Ae.  
scutellaris,  Ae.  aegypti  mosquitoes  have  been  shown  to  be  the  most  efficient  mosquito  
vectors  for  epidemic  DENV  primarily  due  to  their  domestic  lifestyle  and  feeding  
behavior  (Gubler,  1997).  The  female  Ae.  aegypti  mosquitoes  are  known  to  be  very  
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nervous  feeders  that  commonly  break  up  a  single  feeding  event  into  multiple  short  
events  and  often  times  from  multiple  sources  (Gubler,  2006).  This  behavior  allows  for  
the  rapid  transmission  of  DENV  to  multiple  people  in  a  short  period  of  time.    
Furthermore,  Ae.  aegypti  mosquitoes  prefer  to  lay  their  eggs  in  artificial  containers  
containing  water  such  as  cisterns,  tires,  trash  and  flower  pots  –  items  that  are  commonly  
found  in  residential  and  urban  areas  (Gubler,  2006).    
Once  an  individual  is  infected  with  DENV  through  a  mosquito  bite,  the  virus  
enters  an  incubation  period  lasting  up  to  two  weeks  (average  4-­‐‑7  days)  before  onset  of  
illness.  This  is  known  as  the  intrinsic  incubation  period  (IIP)  (Siler  et  al.,  1926;  Sabin,  
1952).  With  onset  of  fever,  the  individual  enters  the  acute  febrile  viremic  stage  when  the  
person  can  infect  mosquitoes  that  feed  on  them.  Once  the  mosquito  ingests  virus  with  
infected  blood,  the  virus  begins  replicating  virions  in  the  midgut  epithelial  cells  
(Ramirez  et  al.,  2009).  The  virions  then  enter  all  areas  of  the  hemocoel  and  ultimately  
infect  the  salivary  glands  before  the  mosquito  becomes  infective  and  develops  the  ability  
to  transmit  virus  to  another  person.  This  is  known  as  the  extrinsic  incubation  period  




1.3  Study  Country:  Sri  Lanka  
The  Democratic  Socialist  Republic  of  Sri  Lanka,  or  Sri  Lanka  as  it  is  commonly  
known,  is  an  island  country  of  65,610  km2  located  off  of  the  coast  of  the  Southeastern  tip  
of  India  in  the  Indian  Ocean  (Figure  5).  According  to  the  World  Bank,  the  total  
population  is  20,328,000,  making  the  country  the  57th  most  populous  in  the  world.  
Despite  its  classification  as  a  lower  middle-­‐‑income  country,  Sri  Lanka  is  beginning  to  
show  the  vital  characteristics  characteristic  of  developed  nations.    
  
Figure  5:  Map  of  Sri  Lanka  
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1.3.1 Dengue Burden in Sri Lanka 
Although  the  majority  of  dengue  cases  are  not  fatal,  the  cyclical  epidemic  
breakouts  since  the  early  2000s  are  of  great  concern.  The  first  serologically  confirmed  
dengue  fever  case  was  reported  in  1962  with  the  first  epidemic  of  dengue  taking  place  
from  1965-­‐‑1968  (Vitarana  et  al.,  1997).  Prior  to  1989,  DHF  was  rare  in  the  Indian  
subcontinent.  Since  1989,  especially  in  Sri  Lanka,  there  has  been  a  dramatic  increase  in  
the  frequency  of  DHF  and  this  region  has  been  considered  endemic  ever  since  (Messer  et  
al.  2002;  Vitrana  et  al.,  1997).  Sri  Lanka  experienced  its  first  epidemic  with  DHF  in  1989  
with  203  cases  and  20  deaths  and  then  again  in  2004  with  15,463  cases  and  88  deaths,  
with  DENV  2  and  3  responsible  for  most  cases  (Wichmann  et  al.,  2009;  Kanakaratne  et  
al.,  2009;  Epidemiology  Unit  of  Sri  Lanka).  A  significantly  larger  epidemic  was  observed  
in  2009  with  35,008  reported  cases  and  346  deaths,  mainly  caused  by  a  new  genotype  of  
DENV  1  (Tissera  et  al.,  2011).  
Sri  Lanka  generally  experiences  two  monsoon  seasons  annually,  one  spanning  
the  months  of  May  through  July  and  the  other  spanning  from  late  December  through  
February.  With  the  heavy  rain  and  already  humid  tropical  climate,  monsoon  seasons  
prove  to  be  optimal  times  for  mosquito  breeding.  Dengue  cases  have  peaked  during  
these  monsoon  seasons  as  highlighted  from  the  number  of  cases  reported  to  Colombo  
(Figure  7).  The  summer  monsoon  season  has  historically  been  associated  with  larger  
dengue  outbreaks,  however,  in  recent  years,  the  winter  monsoon  season  has  also  started  
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to  show  equally  impactful  outbreaks  (Figure  8).  In  the  most  recent  epidemic  of  2012  
there  were  44,456  reported  cases  with  264  deaths  (Epidemiological  Unit  of  Sri  Lanka).  
For  the  year  2013,  31,975  suspected  dengue  cases  were  reported  with  51.63%  of  the  cases  
coming  from  the  Western  province  (Epidemiological  Unit  of  Sri  Lanka).  
  
Figure  6:  Number  of  cases  reported  to  Colombo  between  2004  and  2010  
(Epidemiology  Unit  of  Sri  Lanka)  
  
Figure  7:  Number  of  cases  reported  to  Colombo  between  2010  and  2014  
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The  rapid  change  in  spatial  representation  of  dengue  cases  within  a  10-­‐‑year  span  
from  1996  to  2007  reveals  the  heavy  concentration  of  cases  in  the  Western  Province,  
centering  on  the  capital  city,  Colombo  (Gubler  2004;  Epidemiology  Unit  of  Sri  Lanka;  
World  Health  Organization,  Figure  9).  On  average,  close  to  50%  of  all  dengue  cases  
occur  largely  in  and  around  Colombo,  in  the  central  region  by  Kandy  and  along  the  
southwestern  shore.  Incidence  is  higher  during  the  annual  monsoon  seasons,  May  
through  July,  which  leads  to  higher  humidity  and  optimal  breeding  sites  for  mosquitoes  
(Epidemiology  Unit  of  Sri  Lanka;  Guha-­‐‑Sapir  et  al.,  2005).    
  
Figure  8:  Spatial  representation  of  annual  dengue  cases  from  1996-­‐‑2007  





Figure  9:  Spatial  representation  of  annual  DEN/DHF  cases  reported  to  
Colombo  from  2010-­‐‑2013  (Epidemiology  Unit  of  Sri  Lanka)  
  
Interchanging  dominant  serotypes  have  been  observed  with  DENV2  detected  in  
the  1980s  followed  by  DENV3  for  roughly  two  decades  before  leading  to  the  current  
DENV1  epidemic  (Kanakaratne  et  al.,  2009;  Messer  et  al.,  2003).  In  the  case  of  DENV-­‐‑3,  
strain  difference  within  the  serotype  has  been  linked  to  the  epidemics  in  Sri  Lanka,  
suggesting  that  circulating  genotype  differences  in  DENV-­‐‑3  caused  the  recent  spike  in  
large  outbreaks  associated  with  severe  disease  from  1989-­‐‑2004  (Messer  et  al.,  2002;  
Messer  et  al.,  2003).  During  the  epidemic  of  2009,  a  genotype  1  strain  of  DENV1  emerged  
and  has  been  implicated  as  a  significant  contributor  to  increased  circulation  of  DENV  
(Tissera  et  al.,  2011).  The  re-­‐‑emergence  of  DHF  cases  associated  with  strain  variations  in  
an  endemic  area  like  Sri  Lanka  illustrates  the  importance  of  genetic  surveillance  of  
dengue  infections  (Messer  et  al.,  2002).    
The  age  groups  that  have  mostly  been  affected  by  dengue  historically  have  been  
the  youth.  As  of  1997,  those  under  15  years  of  age  accounted  for  65%  of  dengue  cases  
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with  the  highest  numbers  of  cases  in  the  5-­‐‑9  years  group  (Vitarana  et  al.,  1997).  Since  the  
early  2000s,  however,  not  only  has  the  number  of  total  cases  increased,  but  the  
proportion  of  dengue  cases  for  those  over  15  years  of  age  surpassed  the  under  15  years  
of  age  (Epidemiology  Unit  of  Sri  Lanka).  In  a  study  from  Colombo,  the  change  in  
percentage  of  age  groups  affected  is  illustrated  through  the  two  groups  that  have  been  
most  affected:  the  under  age-­‐‑5  group  and  the  25-­‐‑35  age  group  (Kanakaratne  et  al.,  2009).  
This  change  in  affected  population  is  of  great  concern  as  the  economic  success  that  Sri  
Lanka  has  been  experiencing  is  primarily  due  to  the  large  work  force  created  by  the  
demographic  bonus.  The  increased  urbanization  that  Sri  Lanka  is  facing  with  an  influx  
of  serologically  naïve  people  into  urban  areas  like  Colombo  suggest  a  reason  behind  this  
age  shift.  If  the  incidence  of  cases  is  high  in  the  work  force  for  a  communicable  disease,  
the  susceptibility  of  contracting  the  disease  increases,  especially  in  densely  populated  
urban  areas.    This  poses  a  problem  not  only  for  the  people  who  are  immediately  
affected,  but  also  to  the  population  as  a  whole,  in  terms  of  disease  spread.  
Governmental  support  for  dengue  control  has  increased  over  the  years  with  
prevention  programs  specifically  targeting  the  removal  of  breeding  sites  enforced  on  a  
national  scale.  Along  with  passive  disease  surveillance,  vector  control  efforts  have  
increased  through  a  varying  degree  of  solid  waste  disposal  and  container  removal  
programs  by  district  (Epidemiologic  Unit,  2004).  Public  awareness  of  dengue  has  also  
increased  through  the  help  of  media  over  the  years,  but  there  is  always  room  for  
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improvement  in  boosting  understanding  and  practicing  of  removal  of  breeding  sites  
(Arunachalam  et  al.,  2010;  Gunasekara  et  al.,  2012).  Despite  the  rise  in  public  awareness,  
prevention  programs  and  improvements  in  medical  knowledge,  the  number  of  dengue  
cases  in  Sri  Lanka  has  continued  to  increase,  making  dengue  illness  a  growing  public  
health  concern.  
  
1.4  Study  Objective  and  Aims  
In  order  to  better  understand  the  current  situation  with  dengue  fever,  as  well  as  other  
febrile  illness  in  southern  Sri  Lanka,  a  longitudinal,  prospective  study  of  febrile  patients  
at  the  Teaching  Hospital  of  Karapitiya  (THK)  was  initiated  in  June  2012.  We  performed  a  
sub-­‐‑study  in  this  larger  surveillance  study  with  a  focus  on  dengue  surveillance  as  Sri  
Lanka  has  been  experiencing  cyclical  epidemics  of  dengue  for  several  decades.  Through  
serological  and  molecular  assessments,  we  predicted  the  current  dengue  situation  to  
differ  in  serotype  distribution  compared  to  our  pilot  study  in  2007.  We  further  sought  to  
provide  insight  into  virus  strain  dynamics  by  conducting  full  genome  sequencing  for  
selected  samples  from  two  study  sites  (Colombo  and  Galle)  in  Sri  Lanka.  We  
hypothesized  that  strains  from  Galle  would  be  more  similar  to  each  other  as  compared  
to  those  from  Colombo,  which  suggest  strain  divergence  from  Colombo  and  the  
possibility  of  local  transmission.  
  
  18  
2. Aim 1: Dengue Season 2012-2013 
 
2.1 Study Population 
Beginning  in  June  2012,  febrile  patients  (T>38.0˚C)  over  1  year  of  age  were  recruited  from  
the  Teaching  Hospital  Karapitiya  in  Galle,  Sri  Lanka  as  part  of  a  collaborative  program  
between  Ruhuna  University,  Duke  University,  Duke-­‐‑NUS  Graduate  Medical  School,  
and  Johns  Hopkins  University.  Ethics  review  and  approval  was  obtained  from  each  of  
the  participating  institutions.  The  study  was  funded  through  a  grant  from  the  Office  of  
Naval  Research  to  the  Program  in  Emerging  Infectious  Diseases,  Duke-­‐‑NUS  Graduate  
Medical  School,  Singapore,  and  in  part  by  a  block  grant  from  the  Singapore  Ministry  of  
Health  to  Duke-­‐‑NUS  Graduate  Medical  School.  
 
2.2 Sample Collection 
Upon  receiving  informed  consent  from  febrile  patients,  investigators  completed  a  
standardized  instrument  including  the  collection  of  demographic,  clinical,  and  
epidemiological  data.  Patients  additionally  returned  for  a  follow  up  visit.  Blood,  urine  
and  respiratory  samples  were  collected  at  the  acute  visit  and  serum  additionally  at  the  
convalescent  visit.    
  19  
 
2.3 Laboratory-Based Testing 
Laboratory  testing  for  both  acute  and  convalescent  samples  were  conducted  at  Duke-­‐‑
NUS  Graduate  Medical  School  as  previously  described  (Gubler  et  al.,  1984;  Khan  et  al.,  
2013;  Reller  et  al.,  2012).  Serological  testing  included  dengue  IgM  and  IgG  antibody  
testing  through  ELISAs.  Additional  DENV  isolation  and  molecular  testing  was  done  for  
serotypic  analysis  (Gubler,  1984;  Johnson  et  al.,  2005).  
 
2.3.1 Dengue Serology 
Dengue  serology  consisted  of  both  the  IgM  and  IgG  antibody  testing.  Briefly  for  dengue  
IgM  capture  ELISA,  inner  60  wells  of  a  96-­‐‑well  plate  were  coated  overnight  (4°C)  with  
75µμL/well  of  goat  anti-­‐‑human  IgM  antibodies  diluted  at  1:2000  in  a  carbonate  buffer  (pH  
9.6).  Plates  were  blocked  with  200  µμL/well  of  blocking  buffer  (5%  non-­‐‑fat  dairy  milk  
(NFDM)  in  1x  phosphate  buffered  saline  (PBS)  and  0.005%  Tween  20).  Plates  were  
washed  5x  with  1xPBS  before  diluted  serum  (1:40)  was  loaded  in  triplicate  and  
incubated  (37°C  for  1  hour).  Unbound  antibody  was  washed  prior  to  overnight  
incubation  with  a  mixture  of  DEN1-­‐‑4  antigens  and  mouse  anti-­‐‑flavivirus  IgG  antibodies.  
Plates  were  washed  before  adding  50  µμL/well  of  anti-­‐‑flavivirus  horseradish  peroxidase  
(HRP)  and  incubated  (37°C  for  1  hour).  After  final  washing,  optical  density  (OD)  was  
measured  at  450nm  upon  final  incubation  with  tetramethylbenzidine  (TMB)  substrates.  
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For  dengue  IgG  ELISA,  96-­‐‑well  plates  were  coated  overnight  (4°C)  with  
100µμL/well  of  dengue  2  purified  antigen  diluted  to  117.6ng/mL  in  carbonate  coating  
buffer  (pH  9.6).  Plates  were  washed  5x  with  1xPBS  and  0.05%  Tween  20  before  blocking  
with  100  µμL/well  with  1%  NFDM  and  1xPBS.  After  subsequent  washing,  50µμL  of  diluted  
serum  and  controls  (1:100  in  0.5%NFDM  in  1xPBS)  were  added  as  duplicates  and  
triplicates,  respectively,  and  incubated  (37°C  for  1  hour).  Unbound  antigens  were  
washed  and  25µμL/well  of  goat  anti-­‐‑human  IgG  HRP  antibody  at  1:1000  in  blocking  
buffer  was  added  and  plates  were  incubated.  After  final  washing,  OD  was  measured  at  
450nm  upon  final  incubation  with  TMB  substrates.    
  
2.3.2 Dengue Virus Isolation 
Isolation  of  DENV  was  conducted  by  inoculating  C6/36  cell  lines  with  acute  sera  from  
seroconverting  patients.  Briefly,  20µμL  of  acute  serum  was  diluted  with  180µμL  of  
maintenance  medium  and  added  to  C6/36  cells.  Flasks  were  incubated  at  33°C  for  10  
days  with  daily  observation  for  cytopathic  effects.  Cells  were  tested  for  DENV  with  
serotype-­‐‑specific  monoclonal  antibodies  using  an  indirect  immunofluorescent  antibody  
test.  Supernatant  were  harvested  and  stored  at  -­‐‑80°C.    
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2.3.3 Dengue PCR 
Viral  RNA  for  both  Pan-­‐‑Dengue  and  Pan-­‐‑Flavi  assays  were  extracted  from  acute  sera  
using  the  QIAamp  Viral  RNA  Mini  kit  (QIAGEN,  Valencia,  CA)  following  the  
manufacturer’s  protocols.  The  Pan-­‐‑Dengue  assay,  a  four-­‐‑plex  real-­‐‑time  RT-­‐‑PCR  
(TaqMan)  assay,  was  performed  on  all  acute  sera  to  confirm  DENV  serotype.  Briefly,  
serotype-­‐‑specific  DENV  primers  and  flurogenic  probes  were  combined  with  viral  RNA  
to  determine  DENV  serotype.  Acute  sera  that  were  negative  on  Pan-­‐‑Dengue  were  tested  
on  the  Pan-­‐‑Flavi  assay,  a  single-­‐‑plex  TaqMan  qPCR  assay.  Briefly,  Pan-­‐‑Flavi  primers,  
Pan-­‐‑Flavi  probe  was  combined  with  viral  RNA.  PCR  product  was  separated  using  a  1%  
TAE  gel  and  sequenced.  Sequences  were  blasted  in  PubMed  to  determine  DENV  
serotype.  
 
2.3.4 Laboratory Interpretation 
We  defined  acute  dengue  as  a  case  where  virus  isolation  was  positive,  PCR  was  positive,  
and/or  there  was  a  seroconversion  by  IgG  or  IgM.  Acute  primary  infection  was  defined  
as  acute  dengue  with  absence  of  IgG  antibodies  in  acute  sera.  Those  IgG  or  IgM  positive  
in  both  the  acute  and  convalescent  sera  were  classified  as  acute  secondary  vs.  past  
dengue.  Seroconversion  was  defined  through  negative  results  on  acute  IgG  and  IgM  
ELISA  and  positive  result  on  convalescent  IgG  and  IgM  ELISA.  Seroprevalence  was  
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defined  for  those  with  IgG  positive  results  in  the  acute  sera.  For  dengue  IgM  ELISA,  one  
positive  and  one  negative  control  were  tested  on  each  plate  and  were  determined  
positive  when  mean  OD  value  for  the  serum  reacted  on  DENV  antigen  was  at  least  twice  
the  mean  of  the  OD  value  for  serum  reacted  on  normal  mouse  brain  antigen.  For  dengue  
IgG  ELISA,  two  positive  controls  and  one  negative  control  were  tested  simultaneously  
per  plate.  Positive  calls  were  made  when  mean  OD  values  were  higher  than  the  
mean+2SD  value  for  the  negative  serum  control  per  plate.  For  fluorescence  assays,  a  
four-­‐‑tier  scoring  method  was  used  where  complete  green  fluorescence  indicated  strong  
positive  and  complete  lack  of  green  fluorescence  indicated  strong  negative.  Varying  
levels  of  fluorescence  were  subjectively  scored  compared  to  the  positive  and  negative.  
 
2.3.5 Full Genome Sequencing 
Samples  for  full  genome  sequencing  were  selected  to  evenly  cover  a  temporal  range  
from  May  2012  through  March  2013  and  were  chosen  based  on  a  lower  Ct  value  for  the  
Pan-­‐‑Dengue  assay  using  the  assumption  that  lower  Ct  values  indicates  higher  viremia.  
Procedures  for  full  genome  sequencing  were  based  off  of  a  method  for  
sequencing  the  entire  genome  of  all  four  DENV  serotypes  (Christenbury  et  al.,  2010).    
DENV  RNA  was  extracted  primarily  from  acute  sera  but  also  from  aliquoted  culture  
supernatant  using  the  QIAamp®  Viral  RNA  Mini  Kit  (Qiagen™,  Valencia,  CA,  USA)  in  
accordance  to  the  manufacturer’s  protocol  and  was  stored  at  -­‐‑80°C  until  further  use.  
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cDNA  synthesis  was  executed  using  SuperScript™  III  First-­‐‑Strand  Synthesis  System  for  
RT-­‐‑PCR  (Invitrogen™,  Carlsbad,  CA,  USA).  8  µμL  of  viral  RNA  was  combined  with  1µμL  
of  10  µμM  gene-­‐‑specific  synthetic  oligonucleotide  primer  and  1  µμL  of  10mM  dNTP  mix  in  
0.2  mL  RNAse-­‐‑free  microtubes.  The  final  volume  of  10  µμL  was  incubated  at  65°C  for  5  
minutes  for  denaturation  in  a  Veriti  96Well  Thermal  Cycler  from  Applied  Biosystems™  
(Foster  City,  Ca,  USA)  before  placing  on  ice  for  at  least  one  minute.  cDNA  synthesis  mix  
consisting  of  2  µμL  of  10x  RT  Buffer,  4  µμL  of  25mM  MgCl2,  2  µμL  0.1M  DTT,  1  µμL  
RNaseOUT™  and  1  µμL  of  SuperScript™  III  RT  was  mixed  in  a  separate  microtube  and  
added  to  the  denatured  RNA  mixture  on  ice.  The  RNA  mixture  with  cDNA  synthesis  
mix  totaling  a  volume  of  20  µμL  was  incubated  at  50°C  for  50  minutes  for  cDNA  synthesis  
and  85°C  for  5  minutes  for  reaction  termination  on  a  Veriti  96  Well  Thermal  Cycler.  1  µμL  
of  RNase  H  was  added  to  each  microtube  and  incubated  at  37°C  for  20  minutes  to  
remove  RNA  hybrid  molecules.  First-­‐‑strand  cDNA  synthesis  reactions  were  stored  at  -­‐‑
80°C  until  further  use.  
The  DENV  full  genome  for  each  serotype  was  divided  into  five  overlapping  
amplicons.  For  each  amplicon,  2  µμL  of  cDNA  was  mixed  with  5  µμL  of  10x  PfuUltra  II  
reaction  buffer,  2.5  µμL  of  10  µμM  dNTP  mix,  1  µμL  of  10  µμM  forward  primer,  1  µμL  of  10  
µμM  reverse  primer,  1  µμL  of  PfuUltra  II  fusion  HS  DNA  polymerase  and  38.5  µμL  of  
distilled  water.  PCR  cycling  parameters  for  the  five  amplicons  can  be  found  in  Appendix  
A.  PCR  products  were  separated  on  a  1%  agarose  TAE  gel  and  visualized  under  UV  
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light  after  staining  with  ethidium  bromide  (representative  gel  images  in  Appendix  B).  
Bands  of  interest  that  were  present  without  non-­‐‑specific  products  were  purified  using  a  
Qiagen  QIAquick®  PCR  Purification  Kit  following  manufacturer’s  protocol.  Purified  
amplicons  were  sequenced  by  Sanger  sequencing  method  (Sanger  et  al.,  1977).  
For  amplicon  creation  and  sequencing,  published  and  unpublished  primers  were  
used  (Christenbury  et  al.,  2010).  Primers  developed  during  this  study  were  created  by  
identifying  highly  conserved  regions  within  the  region  of  interest  after  aligning  multiple  
consensus  full  genome  sequences  for  each  serotype  using  Geneious®  R6    (Biomatters  
Ltd.  Auckland,  NZ).  A  full  list  of  sequencing  primers  can  be  found  in  Appendix  C.    
  
2.4 Analyses 
Statistical  analyses  were  performed  on  Stata  IC  12.0  (StataCorp,  College  Station,  TX).  
Categorical  variables  were  compared  by  the  χ2  test  or  Fisher  exact  test.  Continuous  
variables  were  analyzed  by  t-­‐‑test  or  Kruskal-­‐‑Wallis  test.  
For  full  genome  sequencing,  consensus  sequences  created  through  alignment  
with  reference  genomes  were  compared  to  other  strains  available  in  GenBank  (National  
Center  for  Biotechnology  Information)  to  generate  maximum  likelihood  phylogenetic  
trees.  Comparisons  were  conducted  using  the  E-­‐‑gene  region  only  similar  to  what  has  





3.1 2012-2013 Dengue Season 
Enrollment  began  at  the  Teaching  Hospital  of  Karapitiya  (THK)  at  the  end  of  June  2012  
and  has  been  ongoing  since.  Data  presented  here  reflect  the  first  year  of  study,  from  June  
2012  through  June  2013.  Distribution  of  cases  show  a  higher  enrollment  in  July  and  
August  2012  compared  to  the  remainder  of  the  first  year  (Figure  10).  Selected  descriptive  
statistics  of  the  first  year  of  samples  with  laboratory  confirmation  are  shown  in  Table  2.    
  
  
Figure  10:  Enrollment  graph  from  June  2012  -­‐‑  June  2013  (study  started  at  the  
end  of  June  2012)  
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or	  Past	  Dengue	  
(n=123)	  
No	  Dengue	  
(n=24)	   p-­‐value	  
Median	  Age,	  years	  (IQR)	   31.2	  (20.4	  -­‐	  43.5)	   42.5	  (28.0	  -­‐	  54.4)	   11.8	  (7.3	  -­‐	  16.0)	   <0.001	  
Median	  Days	  of	  Fever	  (IQR)	   5	  (3	  -­‐	  6)	   5	  (4-­‐7)	   4	  (2	  -­‐	  5)	   0.0055	  
Median	  Distance	  to	  THK,	  
km	  (IQR)	   30	  (10-­‐50)	   20	  (8-­‐34)	   13	  (4-­‐25)	   0.001	  
Median	  Days	  to	  Conv.	  Visit	  
(IQR)	   24	  (18-­‐39)	   26	  (18-­‐43)	   26	  (19-­‐28)	   0.383	  
Sex	  
	   	   	  
0.974	  
Male	   64.4	   64.2	   66.7	  
	  Female	   35.6	   35.8	   33.3	  
	  Occupation	   	  	   	  	   	  	   0.304	  
Housewife	   16.8	   18.6	   0	  
	  School	   5	   4.4	   0	  
	  Student	   3.2	   0.9	   0	  
	  Factory	  Laborer	   11.4	   13.3	   25	  
	  Agricultural	  Laborer	   13.6	   13.3	   0	  
	  Merchant	   8.6	   8.9	   0	  
	  Law	  Enforcement	   4.6	   3.5	   0	  
	  Construction	  Worker	   2.3	   4.4	   25	  
	  Other	   25.5	   20.4	   0	  
	  Retired	   0.5	   2.7	   0	  
	  Unemployed	   7.73	   8.9	   50	  
	  Education	   	  	   	  	   	  	   0.064	  
Less	  than	  O/L	   43.7	   50.4	   75	  
	  O/L	   27.8	   18.7	   20.8	  
	  A/L	   23.7	   22.8	   4.2	  
	  Above	  A/L	   4.4	   7.3	   0	  
	  Travel	   	  	   	  	   	  	   0.818	  
Provincial	   12.6	   8.1	   4.2	  
	  National	   15.9	   15.5	   12.5	  
	  None	   70	   75.6	   83.3	  




Analysis  of  the  likelihood  of  a  patient  attending  their  convalescent  visit  did  not  
differ  based  on  sex,  age,  occupation  or  residence  area.  However,  increased  likelihood  of  
attending  their  convalescent  visit  was  found  for  children  (P=0.026),  those  with  less  than  
O/L  education  (P=0.001)  and  those  living  less  than  10km  from  THK  (P=<0.001).    
The  days  of  fever  prior  to  enrollment  to  the  study  were  also  analyzed  with  
selected  variables  and  found  to  not  differ  for  sex,  occupation,  type  of  residence  and  
education.  However,  shorter  days  of  fever  were  observed  for  children  (P=0.0001)  and  
those  who  live  less  than  10km  from  THK  (P=0.0098).  
Distribution  of  the  final  clinical  diagnosis  upon  discharge  showed  24.2%  of  all  
diagnosis  to  be  dengue  and  more  than  50%  of  all  diagnoses  consisted  of  viral  fevers  
(Table  3).    
Table  3:  Final  Clinical  Diagnosis  Upon  Hospital  Discharge  
Final	  Diagnosis	   Frequency	   Percentage	  
Dengue	   284	   24.2%	  
Other	  Viral	  Fevers	   377	   32.1%	  
Bacteremia	   10	   0.9%	  
Scrub	  Typhus	   17	   1.5%	  
Atypical	  Pneumonia	   12	   1.0%	  
Lower	  Repiratory	  
Illness	   129	   11.0%	  
Meningitis/Encephalitis	   15	   1.3%	  
Leptospirosis	   97	   8.3%	  
Rickettsiae	   3	   0.3%	  
Upper	  Respiratory	  
Illness	   64	   5.5%	  
Other	   158	   13.5%	  
missing	   9	   0.8%	  
  
  28  
620  samples  of  the  1175  enrolled  in  the  first  year  have  been  tested  further  at  
Duke-­‐‑NUS  Graduate  Medical  School  where  dengue  serotype  was  confirmed  through  
Pan-­‐‑Dengue  and  Pan-­‐‑Flavi  PCR  assays.  Of  the  620  tested,  55.3%  were  found  to  be  
dengue  positive.  The  breakdown  of  dengue  serotypes  showed  93.8%  to  be  DENV1  and  
6.2%  to  be  DENV4  (Table  3).  Days  of  fever  prior  to  enrollment,  with  a  median  of  5  days,  
did  not  differ  across  serotypes  (P=0.229).  
  
  
Table  4:  Dengue  Serotype  Observed  in  Dengue  Season  2012-­‐‑2013  (n=620)  
Dengue	  Serotype	   Frequency	   Percentage	  
DENV1	   321	   51.9%	  
DENV4	   21	   3.4%	  
Negative	   276	   44.7%	  
  
Amongst  the  1175  enrolled,  paired  sera  –  both  acute  and  convalescent  sera  –  
were  available  for  417  at  the  time  of  analysis.  Dengue  serology  was  conducted  on  the  
paired  sera  and  showed  that  acute  dengue  was  present  in  271  (64.8%)  of  the  paired  sera,  
of  which  24.0%  were  primary  infections.  Probability  of  acute  dengue  did  not  differ  by  
sex  (P=1),  but  was  higher  for  children  (P<0.001)  and  urban  areas  (P=0.009).  Overall  
seroprevalence  for  dengue  was  79.9%  where  the  largest  proportion  was  observed  in  the  
20-­‐‑29  year  age  group  with  a  seroprevalence  of  30.3%  (Figure  11).  Seroprevalence  
statistically  differed  amongst  the  different  age  groups  but  not  for  other  selected  
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variables  including  sex,  education  level,  residence  area,  occupation  and  distance  from  
THK.  
  
Figure  11:  Distribution  of  dengue  cases  by  age  group  (Blue  -­‐‑  No  dengue;  Red  -­‐‑  
Acute  dengue;  Green  -­‐‑  Past  dengue)  
 
3.2 Full Genome Sequencing 
Phylogenetic  analysis  using  full  genome  sequences  were  conducted  for  40  viruses  
equally  covering  representative  DENV1  and  DENV4  serotypes.  Half  of  the  sequences  
came  from  the  present  Galle  study  and  the  other  half  from  a  separate  study  based  in  
Colombo,  Sri  Lanka.  No  difference  between  sex  and  age  of  the  patients  was  observed  
nor  was  there  a  statistical  difference  between  days  of  fever  prior  to  enrollment  between  
samples  collected  from  Galle  and  Colombo  for  each  serotype.  
   A  maximum  likelihood  mapping  of  the  sequences  was  conduced  for  both  
DENV1  and  DENV4  using  the  E-­‐‑gene  sequences.  Two  genotypes  of  DENV1,  genotype  1  
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and  genotype  5  were  found  amongst  the  20  DENV1  samples  (Figure  11).  For  DENV4  
sequences,  all  viruses  belonged  to  genotype  1  (Figure  12).    
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Figure  12:  Phylogeny  of  DENV1  samples  (red  indicates  samples  from  Colombo  




Figure  13:  Phylogeny  of  DENV4  samples  (red  indicates  samples  from  Colombo  






Through  the  enrollment  of  febrile  patients,  we  sought  to  characterize  dengue  in  and  
around  Galle,  Sri  Lanka.  Laboratory  testing  of  paired  sera  concluded  that  overall  
seroprevalence  for  dengue  in  this  cohort  is  79.9%,  which  not  only  increased  with  age  
similar  to  what  was  previously  found  in  the  same  area,  but  also  was  a  higher  percentage  
than  what  was  seen  in  2007  (Reller,  2012).  Serotype-­‐‑specific  analysis  showed  the  
predominance  of  DENV1  in  the  current  study,  which  was  first  identified  in  Colombo  in  
2009,  but  was  not  present  in  Galle  in  2007.  Strain  analysis  for  selected  samples  further  
confirmed  relatedness  of  current  DENV1  genotype  1  strains  from  both  Colombo  and  
Galle  to  that  of  DENV1  genotype  1  identified  in  Colombo  in  2009.  Phylogenetic  analysis  
of  the  DENV1  and  DENV4  samples  also  shows  possible  strain  clustering  for  some  of  the  
Galle  samples  suggesting  strain  divergence  and  local  transmission.  
In  the  current  study,  compared  to  adults,  children  had  a  higher  probability  of  
seroconversion  of  26.3%  that  decreased  with  increasing  age,  which  is  consistent  with  the  
fact  that  children  have  had  less  time  for  potential  exposure  to  the  virus  as  compared  to  
adults,  thereby  limiting  the  probability  that  they  would  possess  antibodies  against  a  
particular  virus.  Seroprevalence  of  dengue  also  reflected  the  limited  amount  of  time  
children  have  had  for  potential  exposure  as  51.3%  of  children  compared  to  86.7%  of  
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adults  showed  dengue  seroprevalence.  Children  had  an  average  of  4.3  days  of  fever  
prior  to  enrollment,  which  was  found  to  be,  on  average,  one  day  shorter  than  that  of  
adults.    
Among  acute  dengue  cases,  25.2%  of  cases  were  seen  in  the  20-­‐‑29  years  age  
group  followed  by  21.9%  in  the  30-­‐‑39  years  age  group.  20-­‐‑29  years  age  group  also  saw  
the  largest  proportion  of  chikungunya  cases  at  24.6%.  Our  findings  agree  with  the  
overall  age  shift  from  a  median  age  of  15  years  to  a  median  age  of  25  years  that  has  been  
observed  in  Sri  Lanka  over  the  past  decade  (Sirisena,  2013;  Tam,  2013).  The  larger  
percentage  of  cases  in  the  young  adult  age  group  is  concerning  due  to  its  potential  in  
disrupting  the  work  force  in  addition  to  social  or  familial  consequences.  
Serotype  specific  studies  showed  that  the  serotype  responsible  for  the  majority  of  
the  dengue  cases  in  2012  was  DENV1.  Previously  in  2007,  DENV3  was  observed  in  the  
majority  of  cases  in  the  Southern  Province  (Reller,  2012).  DENV3  has  also  been  thought  
to  be  the  major  cause  behind  severe  epidemics  in  1989  and  2000  when  there  was  clade  
replacement  for  DENV3  genotype  3  from  IIIA  to  IIIB  (Messer  et  al.,  2003;  Kanakaratne,  
2009).  Until  2009,  DENV2  and  DENV3  were  the  predominant  circulating  DENV  
serotypes  accounting  for  86%  of  cases  as  opposed  to  the  7%  by  DENV1  (Sirisena  et  al.,  
2014).  The  most  recent  detection  of  DENV1  in  Sri  Lanka  prior  to  this  study  was  in  2009  
where  a  new  genotype  for  DENV1  was  found  through  E-­‐‑gene  sequencing  of  Colombo  
samples  (Tissera  et  al.,  2011).  Mapping  of  our  results  to  previously  published  sequences  
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indicates  that  a  majority  of  the  DENV1  sequences  belong  to  the  DENV1  genotype  1  
group  (Tissera  et  al.,  2011).  We  also  found  one  case  of  DENV1  genotype  5,  which  is  
separate  from  the  previously  dominant  DENV1  genotype  4  in  Sri  Lanka.    
DENV4  sequence  mapping  showed  that  all  of  the  DENV4  sequences  belong  to  
genotype  1,  or  the  Southeast  Asian  genotype,  which  agrees  with  what  has  previously  
been  found  in  the  region  (Kanakaratne,  2009).  Overall,  there  is  less  literature  available  
for  DENV4  due  to  the  limited  sampling  of  that  serotype.  However,  it  has  been  shown  to  
be  the  predominant  serotype  in  DHF  epidemics  of  1986  and  1998  in  Sri  Lanka  and  
should  be  monitored  appropriately  as  studies  show  the  possible  association  of  DENV4  
with  DHF  during  secondary  infection  (Bennett  et  al.,  2003;  Mongkolsapaya  et  al.,  2003;  
Deitz  et  al.,  1996;  Rigau  et  al.,  1998).        
For  both  DENV1  and  DENV4  genotyped  samples,  clustering  of  Galle  samples  
were  observed  for  a  small  number  of  our  samples.  Such  clustering  may  suggest  a  strain  
divergence  from  those  found  in  Colombo  and  possible  local  transmission  within  Galle,  
but  this  requires  further  investigation.  
 
4.2 Limitations 
Findings  of  this  study  are  limited  to  the  southwestern  region  of  Sri  Lanka.  Although  this  
study  is  a  one-­‐‑site  study,  it  was  held  at  the  largest  tertiary  care  center  in  the  southern  
province  of  Sri  Lanka.  In  addition  to  the  availability  of  free  health  care,  Teaching  
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Hospital  of  Karapitiya  (THK)  sees  a  large  number  of  patients  that  cover  a  wide  
geospatial  spread,  which  can  be  seen  even  within  the  study  patients  through  the  self-­‐‑
reported  distance  to  THK.    Hence,  we  assume  that  a  large  representation  of  presentable  
diseases  for  Southern  Sri  Lanka  can  be  observed  in  the  patients  that  come  to  THK.     
Laboratory  limitations  do  exist  within  the  study,  particularly  for  serological  
testing.  Cross-­‐‑reactions  can  occur  between  dengue  and  other  flaviviruses  like  West  Nile  
virus,  tick-­‐‑borne  encephalitis  virus  and  yellow  fever  virus  due  to  the  limited  specificity  
of  antibodies.  However,  cross-­‐‑reaction  is  not  a  major  concern  in  this  study  since  only  
Japanese  encephalitis  has  been  detected  in  the  region  our  study  encompasses  (CDC,  
2013).  Additionally,  our  definitions  for  serological  interpretation  do  not  include  all  four  
of  the  proposed  laboratory  criteria  set  forth  by  the  WHO.  Adjusting  our  interpretations  
may  increase  the  count  for  acute  dengue;  however,  it  should  not  drastically  change  the  
results  presented  here.    
In  addition  to  serological  testing,  limitations  exist  in  following  the  molecular  
epidemiology  of  the  dengue  serotypes.  We  initially  aimed  to  follow  the  geographic  
spread  of  dengue  serotypes  as  dissemination  of  virus  has  been  associated  with  urban  to  
rural  residencies.  For  DENV1,  genotype  1  was  first  identified  in  Colombo  during  the  
2009  –  2010  dengue  season,  which  was  also  identified  in  our  current  study  in  Galle  
spanning  the  2012-­‐‑2013  dengue  season.  However,  we  are  unable  to  ascertain  when  this  
was  introduced  to  Galle  due  to  the  lack  of  samples  between  early  2008  and  mid-­‐‑2012.  
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Larger  geographic  coverage  over  similar  temporal  spread  is  necessary  to  conduct  a  more  
complete  analysis  of  molecular  epidemiology  of  DENV.  
 
4.3 Implications for Future Research 
In  conclusion,  we  have  aimed  to  describe  the  dengue  season  of  2012  through  
epidemiological  and  laboratory-­‐‑based  findings.  Dengue  serology  conducted  on  a  subset  
of  paired  sera  samples  indicated  acute  dengue  was  present  in  64.83%  of  which  24.02  %  
were  primary  infections.  Significant  difference  in  the  probability  of  acute  dengue  
amongst  children  and  adults  agree  with  the  notion  that  children  are  a  more  vulnerable  
population  than  adults.  However,  our  results  also  show  the  mean  age  of  patients  to  be  
25  years,  reflecting  an  age  shift  from  a  mean  of  15  years  that  has  been  seen  in  various  
parts  of  Sri  Lanka.  Additionally,  acute  dengue  cases  were  found  to  be  different  amongst  
urban  to  rural  residences  agreeing  with  the  possibility  that  historically  urban  diseases  
are  getting  spread  to  more  rural  areas  with  advances  in  transportation  of  goods  and  
people.  Dengue  seroprevalence  in  our  study  population  was  found  to  be  79.9%,  which  
increased  with  age,  as  has  been  previously  found  in  2007  in  our  pilot  study.  
Specific  dengue  serotypes  were  confirmed  through  virus  isolation  and  molecular  
testing  indicating  that  amongst  dengue  positive  samples  93.84%  were  DENV1  and  6.16%  
were  DENV4.  Serotype  distribution  for  this  dengue  season  differed  from  our  study  in  
2007  where  DENV2,  DENV3  and  DENV4  were  identified  with  DENV3  causing  a  
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majority  of  the  dengue  cases  (Reller,  2012).  Further  phylogenetic  analysis  using  full  
genome  sequences  of  a  representative  subset  of  samples  from  2012-­‐‑2013  showed  that  the  
majority  of  DENV1  belonged  to  Asia  genotype  1  and  DENV4  belonged  to  Southeast  
Asia  genotype  1.  Our  findings  agree  with  what  is  found  in  the  literature  and  specifically  
for  DENV1  shows  that  genotype  1  strains  initially  identified  in  Colombo  in  2009-­‐‑2010  
have  now  been  identified  in  Galle  in  the  2012-­‐‑2013  dengue  season.  
Results  from  this  first  year  of  surveillance  hopefully  will  better  inform  the  public  
and  health  officials  on  the  state  of  dengue  in  the  southern  province  of  Sri  Lanka.  
Additionally,  it  is  important  to  monitor  the  evolving  dynamic  of  different  DENV  
serotypes  that  are  causing  cyclical  epidemics  to  better  understand  the  virus.  Such  
information  will  hopefully  benefit  the  scientific  community’s  overall  knowledge  of  the  
virus  as  movements  towards  vector  control,  treatments  and  vaccines  are  made.  The  
continuation  of  surveillance  programs  is  important  in  monitoring  disease-­‐‑causing  
agents.  In  order  to  move  towards  an  active  surveillance  system,  it  is  necessary  to  
incorporate  whole  genome  sequencing  of  representative  samples  across  a  geospatial  and  
temporal  spread  to  better  understand  virus  dynamics  and  to  detect  introduction  of  
evolving  genotypes  of  viruses  so  that  proper  public  health  preparation  can  be  made.  
Combined  with  whole  genome  sequencing,  continued  surveillance  will  likely  remain  
costly.  The  importance  of  monitoring  disease-­‐‑causing  agents,  however,  should  outweigh  
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the  costs  as  the  knowledge  will  ultimately  transform  the  current  paradigm  of  




Table  5:  PCR  Cycling  Parameters  with  Serotype-­‐‑Fragment  Specific  Primer  















2084R	   95°C,	  2min	  
95°C,	  








2259R*	   95°C,	  2min	  
95°C,	  







3033R*	   95°C,	  2min	  
95°C,	  








4561R	   95°C,	  2min	  
95°C,	  







4241R	   95°C,	  2min	  
95°C,	  







7537R	   95°C,	  2min	  
95°C,	  







7537R	   95°C,	  2min	  
95°C,	  







6461R	   95°C,	  2min	  
95°C,	  








6537R*	   95°C,	  2min	  
95°C,	  







7537R	   95°C,	  2min	  
95°C,	  







7537R	   95°C,	  2min	  
95°C,	  







8519R	   95°C,	  2min	  
95°C,	  








8577R*	   95°C,	  2min	  
95°C,	  







9613R	   95°C,	  2min	  
95°C,	  







10693R	   95°C,	  2min	  
95°C,	  







10693R	   95°C,	  2min	  
95°C,	  





	  	   D1-­‐8211F*,	  D1-­‐ 95°C,	  2min	   95°C,	   50°C,	  20s	   72°C,	   72°C,	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10450R*	   2min	   1:30min	   3min	  
	  	  
D1-­‐8994F,	  D1-­‐
10693R	   95°C,	  2min	  
95°C,	  







10693R	   95°C,	  2min	  
95°C,	  







2579R*	   95°C,	  2min	  
95°C,	  








2107R	   95°C,	  2min	  
95°C,	  







4246R	   95°C,	  2min	  
95°C,	  








4926R*	   95°C,	  2min	  
95°C,	  







4246R	   95°C,	  2min	  
95°C,	  







6463R	   95°C,	  2min	  
95°C,	  







6163R	   95°C,	  2min	  
95°C,	  







7349R	   95°C,	  2min	  
95°C,	  







6463R	   95°C,	  2min	  
95°C,	  








7330R*	   95°C,	  2min	  
95°C,	  







7537R	   95°C,	  2min	  
95°C,	  







8531R*	   95°C,	  2min	  
95°C,	  








9708R	   95°C,	  2min	  
95°C,	  







10626R	   95°C,	  2min	  
95°C,	  








10626R	   95°C,	  2min	  
95°C,	  







10643R*	   95°C,	  2min	  
95°C,	  








Table  6:  List  of  Sequencing  Primers  Used  for  Full  Genome  Sequence  (*denotes  
primers  that  were  previously  published  by  Christenbury  et  al.,  2010.  All  other  primers  
are  unpublished  primers  or  were  designed  specifically  for  this  study)  
Serotyp
e Primer Sequence 
DENV-1 d1a4* 5'-CACTCCACTGAGTGAATTCTCTCT-3' 
DENV-1 d1a8* 5′-CAAGTCCCATCAATATAGCTGC-3′ 
DENV-1 d1a12* 5′-CCTCGTCCTCAATCTCTGGTAG-3′  









DENV-1 d1s6* 5′-GGYTCTATAGGAGGRGTGTTCAC-3′ 
DENV-1 d1s8* 5′-ACAAACAGCAGGGCCRTGGCA-3′  
DENV-1 d1s14* 5′-ATGGRGAAAGGAACAACCAG-3′ 
DENV-1 d1s18* 5′-CCACYCATGAAATGTAYTGGGT-3′ 
DENV-1 d1a21* 5'-CATYGCAATRAGRGTGCACAT-3' 
DENV-1 d1s3* 5'-AAACGTTCCGTSGCACTGGC-3' 
DENV-1 d1a20* 5'-CGTCTTCAAGAGTTCAATGTCC-3' 
DENV-1 d1s4* 5'-TGTGTGTCGMCGAACGTT-3' 
DENV-1 d1a19* 5'-GTTTGTGGACRAGCCATGATT-3' 
DENV-1 d1s5* 5'-GCAATGCACACYGCGTTG-3' 
DENV-1 d1a18* 5'-AAAGGTGGYTCYGYYTCAAT-3' 
DENV-1 d1a17* 5'-CCAATGGCYGCTGAYAGTCT-3' 
DENV-1 d1s6* 5'-GGYTCTATAGGAGGRGTGTTCAC-3' 
DENV-1 d1s7* 5'-GGCCCAAGGRAARAAAATG-3' 
DENV-1 d1a16* 5'-CARCTTCCARGTYTCGTTCTT-3' 
DENV-1 d1a15* 5'-GCATYTTTCTRCTCCATCTGGATC-3' 
DENV-1 d1s9* 5'-CCTAGCYYTGATGGCYACTTT-3' 
DENV-1 d1a14* 5'-CCGGAAGCCATGTTGTTTT-3' 
DENV-1 d1s10* 5'-RGCYGGSCCACTAATAGCT-3' 
DENV-1 d1a13* 5'-TTCCACTTCYGGAGGGCT-3' 
DENV-1 d1s10* 5'-RGCYGGSCCACTAATAGCT-3' 
DENV-1 d1a13* 5'-TTCCACTTCYGGAGGGCT-3' 
DENV-1 d1s11* 5'-AAGAGRCTGGAACCRAGYTGGGC-3' 
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DENV-1 d1s12* 5'-AAATGGCAGAGGCGCTCAAGGG-3' 
DENV-1 d1a11* 5'-CRTAGCCTGARTTCCATGATCT-3' 
DENV-1 d1s13* 5'-ACAAAAAAYAAYGACTGGGACTAT-3' 
DENV-1 d1a10* 5'-TCTCTCYGGCTCAAAGAGGG-3' 
DENV-1 d1a9* 5'-CCAGTYARCACAGCTATCAAAGC-3' 
DENV-1 d1s14* 5'-ATGGRGAAAGGAACAACCAG-3' 
DENV-1 d1a9* 5'-CCAGTYARCACAGCTATCAAAGC-3' 
DENV-1 d1s15* 5'-GGATAGCGGCCTCYATCATACT-3' 
DENV-1 d1s16* 5'-GCAAARGCYACTAGAGAAGCTCAA-3' 
DENV-1 d1a7* 5'-CCTACCTCCTCCTARAGATTTCA-3' 
DENV-1 d1s17* 5'-GAAACRACYAAACAYGCAGTG-3' 
DENV-1 d1a6* 5'-AGRACACGTAACGTTCTWCCTTC-3' 
DENV-1 d1a5* 5'-GGRATRACATCCCATGGTTT-3' 
DENV-1 d1s18* 5'-CCACYCATGAAATGTAYTGGGT-3' 
DENV-1 d1s19* 5'-GCCARGTGGTTATGGGGTTT-3' 
DENV-1 d1s20* 5'-GGATGATCTTCAGAATGAGGC-3' 
DENV-1 d1a3* 5'-YACRCARTCATCTCCRCTGAT-3' 
DENV-1 d1s21* 5'-TYATGAAGGATGGGAGGGA-3' 
DENV-1 d1a2* 5'-DTCTTCCCAACTGGAYACATG-3' 
DENV-1 d1s1* 5'-TRGCTCCATCGTGGGGAT-3' 
DENV-1 D1-3F 5'-GGCTATCCTACAAAGTTGCCTCAG-3' 
DENV-1 D1-3927F 5'-GGCTACCTTGCTGTCC-3' 
DENV-1 D1-5986F 5'-GGACAGAAGCAAAAATGCTCC-3' 
DENV-1 D1-8282F 5'-CCAGAATGTTGCTAAATCG-3' 
DENV-1 D1-6645R 5'-GCCATCACGCAGAGTAGG-3' 
DENV-1 D1-7674R 5'-CCCACTCCTTTTATAGG-3' 
DENV-4 d4a3* 5’-TGTGRAARTGGTGGGAGCAAAA-3’ 
DENV-4 d4a8* 5’-ACYTGCCCTAATTGCTTTTCAAA-3’ 
DENV-4 d4a14* 5’-TTGGTRAACYACTCCATTTCC-3’ 









DENV-4 d4s5* 5’-CTCCGTGTAAAGTCCCCATAGAGA-3’ 
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DENV-4 d4s11* 5’-CCTMGCYATAGAACCAGGAAAAAATC-3’ 
DENV-4 d4s16* 5’-AGRACAGCTGCTGGGATCATGA-3’ 
DENV-4 d4s21* 5’-GAAAGACATYCCGCAGTGGGAA-3’ 
DENV-4 d4s2* 5’-AACAAATGCACYCTYATTGCCA-3’ 
DENV-4 d4s3* 5’-TTTGAACTGACYAAGACAACAGC-3’ 
DENV-4 d4s4* 5’-TGGACAGCAGGAGCAGACACAT-3’ 
DENV-4 d4s6* 5’-GYTCCATTGGCAAGATGTTTGAG-3’ 
DENV-4 d4a2* 5’-AACYTGGTGYACAGCCTTTCCC-3’ 
DENV-4 d4a4* 5’-CATGCTGTGTTTCTGCCATCTC-3’ 
DENV-4 d4a6* 5’-TGGGTGTCTCCATTGTGGACTG-3’ 
DENV-4 d4a7* 5’-TACATGACCCAGGTRGACGTGAG-3’ 
DENV-4 d4s7* 5’-GTTGTGTGGYGTCATGGARTGG-3’ 
DENV-4 d4s8* 5’-CATATGGATGAAATTCCGAGAAGGA-3’ 
DENV-4 d4s9* 5’-GGAGATTAGGCCCTTGAGTGAAAA-3’ 
DENV-4 d4s10* 5’-CATTRGTCATGGCTTGGAGGACC-3’ 
DENV-4 d4s12* 5’-GAAACTGGCRCTGATAACAGTRTCA-3’ 
DENV-4 d4a9* 5’-TTTCCCRAAYAACCCTCTTTGC-3’ 
DENV-4 d4a10* 5’-ACCAAACCCACAGCCATTATGC-3’ 
DENV-4 d4a11* 5’-GAGRCCTCCYAGGATGATAGCAC-3’ 
DENV-4 d4a12* 5’-ATGAGCATCTGRCTTTCCAGCAC-3’ 
DENV-4 d4a13* 5’-TCYTGTTDATGATRGGAGARCCAGA-3’ 
DENV-4 d4a15* 5’-TATTGCAGACGCTAGYCTCGCTG-3’ 
DENV-4 d4s13* 5’-CTTSTAGTGTCGCRGCTAGAGGATA-3’ 
DENV-4 d4s14* 5’-TGCYCACTGGACAGAAGCAAAGAT-3’ 
DENV-4 d4s15* 5’-TAGGTGCTATGACAGCMGGYATCT-3’ 
DENV-4 d4s17* 5’-ACCTTGACAGCATCCYTAGTCATG-3’ 
DENV-4 d4a16* 5’-TCAATTGATTGTCTTGTGGGGTC-3’ 
DENV-4 d4a17* 5’-CTTTCCCCTGTGAAGCACCAT-3’ 
DENV-4 d4a19* 5’-TCAACTGGATHACTYTCTTTCCCG-3’ 
DENV-4 d4a20* 5’-TTGTCTTTCCRGCTCCGGGGT-3’ 
DENV-4 d4s18* 5’-GGTCBTATTACATGGCGACACTCA-3’ 
DENV-4 d4s19* 5’-GCACAAAGAAACCTGGCAYTATGA-3’ 
DENV-4 d4s20* 5’-GGAATTTGAAGCCCTGGGTTTT-3’ 
DENV-4 d4s22* 5’-AAAGACATYCCGCAGTGGGA-3’ 
DENV-4 d4a21* 5’-CATCTGTTCYGTGATCAGTTCYTCA-3’ 
DENV-4 d4a22* 5’-ARCCAATTGGCTGTCGTGGT-3’ 
DENV-4 d4a23* 5’-GARTTCCTGGAYARCGGGCA-3’ 
DENV-4 d4a24* 5’-CCATCTYTYAGGGCAGACTTGG-3’ 
DENV-4 d4s23* 5’-GACAAGACTCCAGTCCATTCGTG-3’ 
DENV-4 d4a25* 5’-TTCCGATCAGRTTCCTGACCTG-3’ 
DENV-4 D4F1-28F 5'-GTCTGTGTGGACCGACAAGCACAG-3' 
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DENV-4 D4F1-65F 5'-GCTTGCTTAACACAGTTCTAACAG-3' 
DENV-4 D4-2387F 5'-CCTCAATGGCAATGTCATGC-3' 
DENV-4 D4-3836F 5'-CCATGACAACGGTGCTTTC-3' 
DENV-4 D4-6002F 5'-GATGAAGATCATGCCCACTG-3' 
DENV-4 D4-3532R 5'-GTTTCTGATGTACCCTGTCC-3' 
DENV-4 D4-6163R 5'-CTCTCCATCAATGGCTTGG-3' 
DENV-4 D4-8267R 5'-CCATGGCTCCACCATCTTC-3' 












Representative  images  of  PCR  product  separated  using  1%  agarose  TAE  gel  and  
visualized  under  UV  light  after  staining  with  ethidium  bromide.  1kb  ladders  were  used  






Appendix D  
From  August  through  October  of  2013,  I  engaged  in  a  capacity  building  project  at  the  
University  of  Ruhuna  in  Galle,  Sri  Lanka  as  a  member  of  the  Duke-­‐‑Ruhuna  Febrile  
Illness  Study  Team.  My  primary  objective  was  to  establish  two  in-­‐‑house  ELISA  assays  
that  were  being  used  at  Duke-­‐‑NUS  Medical  School  in  Singapore  with  proper  verification  
methods.  My  secondary  objective  was  to  train  selected  in-­‐‑country  personnel  on  the  two  
ELISA  assays.  
Prior  to  the  project  in  Galle,  I  spent  three  months  at  Duke-­‐‑NUS  Medical  School  in  
Singapore  predominantly  running  the  two  ELISA  assays  for  dengue  serology  –  IgM  and  
IgG  assays.  Through  the  hundreds  of  assays,  I  was  able  to  not  only  demonstrate  
consistency  in  my  experiments  but  to  gain  a  better  understanding  of  the  assay.  Once  
arriving  at  the  University  of  Ruhuna,  I  initially  began  with  a  trial  ELISA  with  a  
commercial  kit  to  get  accustomed  to  the  set-­‐‑up  at  the  laboratory.  I  then  started  testing  
with  the  IgG  ELISA  followed  by  the  IgM  ELISA  making  necessary  adjustments  to  the  
protocols  due  to  resource  limitations.  Notable  adjustments  included  substituting  manual  
washing  to  all  wash  steps  due  to  the  lack  of  an  automatic  washer,  the  creation  of  in-­‐‑
house  controls  for  both  assays  and  the  usage  of  a  full  96-­‐‑well  plate  in  lieu  of  the  inner  60-­‐‑
wells  for  the  IgM  assay. 
After  the  establishment  of  the  two  assays,  selected  samples  from  the  runs  I  had  
completed  in  Singapore  were  selected  to  understand  the  accuracy  of  the  ELISA  assays  at  
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the  University  of  Ruhuna.  This  was  done  in  efforts  to  minimize  the  number  of  variables  
to  the  environment  and  necessary  protocol  adjustments.  Once  results  were  replicated,  
these  same  sera  were  used  for  training  purposes.  
A  total  of  five  in-­‐‑country  individuals  were  trained  in  both  the  IgG  and  IgM  
assay.  After  the  initial  group  training,  training  was  switched  to  an  individual  “one-­‐‑on-­‐‑
one”  basis  to  limit  conversation  to  English  only  –  due  to  my  lack  of  Sinhala  knowledge  
beyond  basic  conversational  phrases.  Given  this  time  constraint,  all  five  individuals  
were  given  the  opportunity  to  run  one  IgG  and  one  IgM  ELISA  test  with  the  exception  of  
one  technician  who  went  on  for  further  training.  This  lab  technician  was  chosen  under  
the  discretion  of  my  supervisor  after  discussing  preliminary  results,  availability  in  terms  
of  other  laboratory  work  and  flexibility  with  time.  This  individual  completed  two  
additional  IgM  tests  where  results  were  replicated  with  100%  accuracy  both  times.  
Aside  from  the  training,  I  was  also  asked  to  test  50  samples  to  which  I  was  
blinded  in  terms  of  results  –  these  samples  were  chosen  from  the  most  recent  shipment  
to  Singapore,  which  arrived  in  Singapore  after  I  had  left.  A  total  of  60  samples  were  
tested  on  the  IgM  assay  after  being  selected  for  volume  availability  and  confirmation  of  
sera  availability  in  Singapore.  A  different  aliquot  of  the  same  samples  were  tested  by  a  
different  researcher  in  Singapore  and  upon  comparison,  results  obtained  in  Galle  were  
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